Demographics | | |
Age (y) | 50 (23–96) | 67 (28–95) |
Female | 209 (80) | 145 (100) |
Vaccine | | |
mRNA vaccine (vs. viral vector vaccine) | 233 (90) | 128 (88) |
2 doses (vs. 1 dose) | 110 (42) | 61 (42) |
Interval between first dose and PET (patients who had 1 dose) (d) | 14 (1–51) | 13 (1–44) |
Interval between second dose and PET (patients who had 2 doses) (d) | 23 (1–67) | 24 (1–67) |
Disease | | |
BC (early vs. advanced stage) | 145 (56) | 54 (37) vs. 91 (63) |
Hematologic malignancy (lymphoma, leukemia, myeloma) | 39 (15) | NA |
Thoracic cancer | 17 (7) | NA |
Digestive cancer | 15 (6) | NA |
Gynecologic cancer | 14 (5) | NA |
Head and neck cancer | 14 (5) | NA |
Other types of cancer (thyroid, sarcoma, melanoma) | 11 (4) | NA |
Nononcologic indications (inflammatory or infectious diseases) | 5 (2) | NA |
Treatment | | |
No specific treatment | 106 (41) | 47 (32) |
Endocrine therapy | 28 (11) | 24 (16.5) |
Chemotherapy | 46 (17.5) | 25 (17.5) |
Targeted therapy | 18 (7) | 9 (6) |
Immune checkpoint inhibitors (single-agent or combined therapies) | 8 (3) | 0 (0) |
Endocrine therapy + targeted therapy | 39 (15) | 37 (26) |
Chemotherapy + targeted therapy | 4 (1.5) | 3 (2) |
Steroids (>10 mg/d of prednisone-equivalent) | 12 (5) | 5 (3) |
Peripheral blood | | |
Interval between blood analysis and PET (d) | 2 (0–28)* | 3 (0–28)† |
ALC (×109/L) | 1.4 (0.3–18.3)* | 1.5 (0.4–5.0)† |
Lymphopenia | 74 (44)* | 41 (39) |
HLNs on 18F-FDG PET/CT | | |
Interval‡ (d) | 17 (0–67) | 19 (0–79) |
Etiology | | |
Vaccine-induced | 90 (35) | 56 (37) |
Tumor-related | 14 (5) | 6 (4) |
Indeterminate | 6 (2) | 6 (4) |
None | 150 (58) | 77 (53) |
HLN SUVmax | 3.7 (2.0–26.3) | 3.7 (2.0–26.3) |